FindTrial
Sign In

ComparisonofSurvivalandSafety between a Neoadjuvant Therapy-based Strategy and Upfront Hepatectomy Followed by Adjuvant TACE for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score-Matched Study

ComparisonofSurvivalandSafety between a Neoadjuvant Therapy-based Strategy and Upfront Hepatectomy Followed by Adjuvant TACE for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score-Matched Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112919
Enrollment
Unknown
Registered
2025-11-21
Start date
2024-07-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Observation Group for Hepatocellular carcinoma combined with portal vein tumor thrombus treatment:None

Sponsors

Guangxi Medical University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Postoperative pathological examination confirmed the diagnosis of HCC (patients with complete pathological response after surgery met the clinical diagnosis of primary liver cancer in neoadjuvant therapy); 3. Pathological confirmation of the presence of portal vein tumor thrombus (confirmed by imaging before conversion therapy); 4. Meet the "surgically resectable" standard; 5. No extrahepatic metastasis or impaired function of important organs; 6. No previous local or systemic anti-tumor treatment has been received.

Exclusion criteria

Exclusion criteria: 1.Patients who have relapsed within two months after surgical resection; 2. Postoperative pathological examination confirmed that the surgical margin was positive. 3. Within 5 years after the operation, other malignant tumors except HCC occur; 4. The follow-up data is incomplete.

Design outcomes

Primary

MeasureTime frame
Overall Survival;Event Free Survival;—

Countries

China

Contacts

Public ContactZhihong Tang

Guangxi Medical University Cancer Hospital

tangzhihong@gxmu.edu.cn+86 771 531 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026